Should I buy or sell Harpoon Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HARP shares. View HARP analyst ratings or view top-rated stocks .

What is Harpoon Therapeutics' stock price target for 2024?

5 analysts have issued 12-month price objectives for Harpoon Therapeutics' stock. Their HARP share price targets range from $13.00 to $45.00. On average, they predict the company's stock price to reach $29.50 in the next year. This suggests a possible upside of 202.9% from the stock's current price. View analysts price targets for HARP or view top-rated stocks among Wall Street analysts .

How have HARP shares performed in 2023?

Harpoon Therapeutics' stock was trading at $7.2570 at the beginning of the year. Since then, HARP shares have increased by 34.2% and is now trading at $9.74. View the best growth stocks for 2023 here .

Are investors shorting Harpoon Therapeutics?

Harpoon Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 255,300 shares, an increase of 7.2% from the October 31st total of 238,200 shares. Based on an average daily volume of 156,700 shares, the days-to-cover ratio is currently 1.6 days. Approximately 1.9% of the company's stock are short sold. View Harpoon Therapeutics' Short Interest .

When is Harpoon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024. View our HARP earnings forecast .

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($3.09) by $2.63. The company earned $4.45 million during the quarter, compared to analyst estimates of $8.33 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 893.55% and a negative net margin of 81.68%.

When did Harpoon Therapeutics' stock split?

Harpoon Therapeutics's stock reverse split on the morning of Tuesday, September 5th 2023. The 1-10 reverse split was announced on Tuesday, September 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?

5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com . Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend.

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE) , Inovio Pharmaceuticals (INO) , Alector (ALEC) , Precision BioSciences (DTIL) , Editas Medicine (EDIT) , Gossamer Bio (GOSS) , Kaleido Biosciences (KLDO) , NVIDIA (NVDA) , Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD) .

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include MPM Bioimpact LLC (8.24%), Kennedy Capital Management LLC (1.37%), Acadian Asset Management LLC (0.20%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ansbert Gadicke , Bioventures 2014 LP Mpm, Georgia Erbez , Holger Wesche , Impact Fund (Cayman) Oncology and Ronald Hunt. View institutional ownership trends .

How do I buy shares of Harpoon Therapeutics?

Shares of HARP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Harpoon Therapeutics Stock Price, News & Analysis (NASDAQ:HARP)

$9.67

-0.95 (-8.95%)

(As of 03:44 PM ET)

Compare

Today's Range: $9.51
▼
$11.50
50-Day Range: $3.29
▼
$12.99
52-Week Range: $3.11
▼
$33.55

Volume: 187,591 shs
Average Volume: 70,955 shs
Market Capitalization: $163.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $29.50

Harpoon Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 202.9% Upside
$29.50 Price Target
Short Interest: Healthy
1.90% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.61
Upright™ Environmental Score
News Sentiment: 1.22
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.93) to ($3.23) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

168th out of 953 stocks

Biological Products, Except Diagnostic Industry

20th out of 148 stocks

3.4

Analyst's Opinion

Consensus Rating
Harpoon Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $29.50, Harpoon Therapeutics has a forecasted upside of 202.9% from its current price of $9.74.
Amount of Analyst Coverage
Harpoon Therapeutics has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.90% of the float of Harpoon Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Harpoon Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Harpoon Therapeutics has recently increased by 7.18%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Harpoon Therapeutics does not currently pay a dividend.
Dividend Growth
Harpoon Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Harpoon Therapeutics has received a 76.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Harpoon Therapeutics is -0.61.

4.0

News and Social Media Coverage

News Sentiment
Harpoon Therapeutics has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Harpoon Therapeutics this week, compared to 1 article on an average week.
Search Interest
14 people have searched for HARP on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.
MarketBeat Follows
5 people have added Harpoon Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Harpoon Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
17.00% of the stock of Harpoon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
74.01% of the stock of Harpoon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Harpoon Therapeutics are expected to decrease in the coming year, from ($1.93) to ($3.23) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Harpoon Therapeutics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Harpoon Therapeutics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Harpoon Therapeutics has a P/B Ratio of 5.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Harpoon Therapeutics Stock (NASDAQ:HARP)

Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company at the forefront of revolutionizing cancer treatment and other diseases. The company is developing a novel T-cell engagers class to use the body's immune system to fight infection.

Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma.

Shares of Harpoon have skyrocketed following the release of data from its Phase 1 clinical trial for HPN217, a single-agent candidate for pretreated patients with relapsed/refractory multiple myeloma (RRMM). The data showed clinical activity and a "tolerable safety profile," with low-grade CRS observed in 29% of patients following the first or second doses of the drug and no incidents of "Grade 3 or higher CRS." Analysts have a consensus price target of $8.75 on the stock, suggesting over 85% upside potential.

Harpoon has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating TriTAC platform technology and soluble T cell receptors. In addition, the company has a preclinical stage product, HPN601, for treating multiple solid tumor indications.

HARP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HARP Stock News Headlines

December 6, 2023 | finance.yahoo.com

ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA

December 6, 2023 | americanbankingnews.com

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Given Consensus Recommendation of "Moderate Buy" by Brokerages

December 6, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

December 5, 2023 | finance.yahoo.com

Harpoon Therapeutics, Inc. (HARP) Upgraded to Strong Buy: What Does It Mean for the Stock?

November 30, 2023 | finance.yahoo.com

Wall Street Analysts Believe Harpoon Therapeutics, Inc. (HARP) Could Rally 40.5%: Here's is How to Trade

November 30, 2023 | finance.yahoo.com

Is it a Good Idea to Invest in Harpoon (HARP) Stock Now?

November 21, 2023 | seekingalpha.com

Harpoon: HPN328 Data In 1st Half Of 2024 Makes This A Must Watch

November 21, 2023 | msn.com

TD Cowen Initiates Coverage of Harpoon Therapeutics (HARP) with Outperform Recommendation

December 6, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

November 15, 2023 | finance.yahoo.com

Fast-paced Momentum Stock Harpoon Therapeutics, Inc. (HARP) Is Still Trading at a Bargain

November 14, 2023 | finance.yahoo.com

Wall Street Analysts See a 92.31% Upside in Harpoon Therapeutics, Inc. (HARP): Can the Stock Really Move This High?

November 11, 2023 | msn.com

Harpoon Therapeutics GAAP EPS of -$0.46, revenue of $4.54M

November 9, 2023 | finance.yahoo.com

Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 4, 2023 | markets.businessinsider.com

Optimistic Financial Outlook and Promising Clinical Developments Drive Buy Rating for Bicycle Therapeutics

November 4, 2023 | markets.businessinsider.com

Bicycle Therapeutics: Strong Financial Standing and Promising Lead Assets Reinforce Buy Rating

November 2, 2023 | finance.yahoo.com

Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

October 28, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Bicycle Therapeutics (BCYC), Abbott Labs (ABT) and VolitionRX (VNRX)

October 25, 2023 | benzinga.com

Harpoon Therapeutics Stock (NASDAQ:HARP), Analyst Ratings, Price Targets, Predictions

October 23, 2023 | markets.businessinsider.com

Harpoon Therapeutics Announces Private Placement Of Up To $150 Mln

October 23, 2023 | marketwatch.com

Harpoon Therapeutics Shares Rise 39% After Positive HPN328 Trial Data

October 23, 2023 | proactiveinvestors.com

Harpoon Therapeutics stock soars on ‘promising’ lung cancer drug results

October 23, 2023 | marketwatch.com

Harpoon Therapeutics to Raise Up to $150 Million in Private Placement

October 23, 2023 | benzinga.com

What's Going On With Harpoon Therapeutics Stock Monday?

October 23, 2023 | msn.com

Harpoon climbs on data for cancer drug (updated)

October 23, 2023 | finance.yahoo.com

Harpoon Therapeutics Announces Up to $150 Million Private Placement

October 21, 2023 | finance.yahoo.com

Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

October 16, 2023 | finance.yahoo.com

Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023

See More Headlines

Receive HARP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/25/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HARP
CUSIP: N/A
CIK: 1708493
Web: www.harpoontx.com
Phone: (650) 443-7400
Fax: N/A
Employees: 50
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $29.50
High Stock Price Target: $45.00
Low Stock Price Target: $13.00
Potential Upside/Downside: +168.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.76)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-67,730,000.00
Net Margins: -81.68%
Pretax Margin: -81.67%
Return on Equity: -893.55%
Return on Assets: -45.98%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.89
Quick Ratio: 1.89

Sales & Book Value

Annual Sales: $37.34 million
Price / Sales: 4.98
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.63 per share
Price / Book: 6.74

Miscellaneous

Outstanding Shares: 16,932,000
Free Float: 14,054,000
Market Cap: $186.08 million
Optionable: Not Optionable
Beta: 2.10

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Ms. Julie M. Eastland M.B.A. (Age 59)
President, CEO, Secretary & Director
Comp: $910.77k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HARP Stock Analysis - Frequently Asked Questions

Should I buy or sell Harpoon Therapeutics stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HARP shares.
View HARP analyst ratings or view top-rated stocks.
What is Harpoon Therapeutics' stock price target for 2024?: 5 analysts have issued 12-month price objectives for Harpoon Therapeutics' stock. Their HARP share price targets range from $13.00 to $45.00. On average, they predict the company's stock price to reach $29.50 in the next year. This suggests a possible upside of 202.9% from the stock's current price.
View analysts price targets for HARP or view top-rated stocks among Wall Street analysts.
How have HARP shares performed in 2023?: Harpoon Therapeutics' stock was trading at $7.2570 at the beginning of the year. Since then, HARP shares have increased by 34.2% and is now trading at $9.74.
View the best growth stocks for 2023 here.
Are investors shorting Harpoon Therapeutics?: Harpoon Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 255,300 shares, an increase of 7.2% from the October 31st total of 238,200 shares. Based on an average daily volume of 156,700 shares, the days-to-cover ratio is currently 1.6 days. Approximately 1.9% of the company's stock are short sold.
View Harpoon Therapeutics' Short Interest.
When is Harpoon Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our HARP earnings forecast.
How were Harpoon Therapeutics' earnings last quarter?: Harpoon Therapeutics, Inc. (NASDAQ:HARP) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($3.09) by $2.63. The company earned $4.45 million during the quarter, compared to analyst estimates of $8.33 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 893.55% and a negative net margin of 81.68%.

When did Harpoon Therapeutics' stock split?: Harpoon Therapeutics's stock reverse split on the morning of Tuesday, September 5th 2023. The 1-10 reverse split was announced on Tuesday, September 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?: 5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend.
What other stocks do shareholders of Harpoon Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).
When did Harpoon Therapeutics IPO?: (HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.
Who are Harpoon Therapeutics' major shareholders?: Harpoon Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include MPM Bioimpact LLC (8.24%), Kennedy Capital Management LLC (1.37%), Acadian Asset Management LLC (0.20%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ansbert Gadicke, Bioventures 2014 LP Mpm, Georgia Erbez, Holger Wesche, Impact Fund (Cayman) Oncology and Ronald Hunt.
View institutional ownership trends.
How do I buy shares of Harpoon Therapeutics?: Shares of HARP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:HARP) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial